VolitionRx Limited (VNRX)
| Market Cap | 24.80M -50.4% |
| Revenue (ttm) | 2.47M +88.5% |
| Net Income | -24.60M |
| EPS | -4.21 |
| Shares Out | 7.92M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 517,936 |
| Open | 2.890 |
| Previous Close | 2.700 |
| Day's Range | 2.760 - 3.260 |
| 52-Week Range | 1.906 - 18.800 |
| Beta | 1.03 |
| Analysts | Buy |
| Price Target | 20.21 (+545.69%) |
| Earnings Date | May 14, 2026 |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s c... [Read more]
Financial Performance
In 2025, VolitionRx's revenue was $1.73 million, an increase of 40.04% compared to the previous year's $1.23 million. Losses were -$23.36 million, -13.39% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for VNRX stock is "Buy." The 12-month stock price target is $20.21, which is an increase of 545.69% from the latest price.
News
VolitionRx Earnings Call Transcript: Q1 2026
Revenue surged 300% year-over-year to $1 million, driven by deferred revenue from the Nu.Q Vet agreement, while operating expenses rose due to R&D and severance costs. Major product milestones included validation of the feline cancer assay and advances in liquid biopsy technology.
VolitionRx Earnings release: Q1 2026
VolitionRx released its Q1 2026 earnings on May 15, 2026, summarizing the period's financial results.
VolitionRx Quarterly report: Q1 2026
VolitionRx has published its Q1 2026 quarterly earnings report on May 15, 2026.
VolitionRx Slides: Investor presentation
VolitionRx has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
VolitionRx reports Q1 revenue $1M, consensus $409,920
Cameron Reynolds, President and Group Chief Executive Officer, said: “We have made strong progress across all of our product pillars during the first quarter and indeed subsequent to quarter end.
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Friday, May 15 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
VolitionRx Proxy statement: Proxy filing
VolitionRx filed a proxy statement on May 13, 2026, providing details for shareholder voting and corporate governance matters.
VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update
Conference call to take place on Friday, May 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
VolitionRx submits manuscript for Nu.Q Vet cancer test in cats
VolitionRx (VNRX) announced submission for peer review a clinical manuscript reporting the accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats, the most common cancer in…
VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats
The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment HENDERSON, Nev., May 6, 2026 /PRNewswire/ -- VolitionRx Limited (...
VolitionRx announces milestone in nucleosomes detection
VolitionRx (VNRX) announces a major technical milestone with the successful detection of nucleosomes in capillary blood from critically ill sepsis patients using its lateral flow prototype. This finge...
Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing
HENDERSON, Nev., April 29, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces a major technical milestone with the succes...
VolitionRx’s compliance plan accepted by NYSE American
VolitionRx (VNRX) announced that on April 22, the NYSE American accepted the company’s plan of compliance for continued listing on the exchange. On February 6, the company received a notice…
VolitionRx Announces Acceptance of Compliance Plan by NYSE American
HENDERSON, Nev., April 23, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that on April 22, 2026, th...
VolitionRx downgraded to Hold from Buy at D. Boral Capital
D. Boral Capital downgraded VolitionRx (VNRX) to Hold from Buy without a price target citing the company’s 1-for-20 reverse stock split, effective April 28. Reverse splits are typically a negative…
Volition Launches rNuQ™ Webshop Broadening Product Range
HENDERSON, Nev., April 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ webshop offering a range o...
VolitionRx price target lowered to $1 from $1.50 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on VolitionRx (VNRX) to $1 from $1.50 and keeps a Buy rating on the shares after the company reported Q4 results. The firm,…
VolitionRx Earnings Call Transcript: Q4 2025
Achieved strong revenue growth and major clinical/commercial milestones in 2025, including first clinical orders for Nu.Q Cancer and NETs, automation breakthroughs in vet diagnostics, and validation of Capture-Seq technology. Focus shifted to commercialization with ongoing cost reductions and multiple licensing deals expected in 2026.
VolitionRx Annual report: Q4 2025
VolitionRx has published its Q4 2025 annual report on April 1, 2026.
VolitionRx Earnings release: Q4 2025
VolitionRx released its Q4 2025 earnings on April 1, 2026, summarizing the period's financial results.
VolitionRx Slides: Corporate presentation
VolitionRx has posted slides in relation to its latest quarterly earnings report, which was published on April 1, 2026.
VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Wednesday, April 1 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium
HENDERSON, Nev., March 31, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has secured an additional €2.0 million (approximately $2.3 ...
Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients
Peer Reviewed Clinical Study for Nu.Q® Biomarkers Published in Shock Journal HENDERSON, Nev., March 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epi...
Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference
HENDERSON, Nev., March 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the presentation of an abstract at the European L...